Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Benzer Materyaller

• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
  Yazar:: Schiff, Michael, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
  Yazar:: Fleischmann, Roy, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
  Yazar:: Fleischmann, Roy, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
  Yazar:: Weinblatt, Michael E, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
  Yazar:: Schiff, Michael, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)